Ilginatinib hydrochloride is primarily used in the field of oncology as a targeted therapy for certain types of cancers. It functions as a potent inhibitor of JAK2, a protein kinase that plays a crucial role in cell signaling pathways associated with cell growth and survival. This makes it particularly effective in treating myeloproliferative neoplasms, a group of blood disorders characterized by the overproduction of blood cells. By inhibiting JAK2, ilginatinib hydrochloride helps to reduce the abnormal proliferation of blood cells, thereby alleviating symptoms and improving patient outcomes. Additionally, it is being investigated for its potential efficacy in other cancers where JAK2 signaling is implicated, offering hope for expanded therapeutic applications in the future.